Early prescription of direct oral anticoagulant for the treatment of intermediate-high risk pulmonary embolism: a multi-center, observational cohort study.

Date publication

octobre 2020

Journal

Thrombosis research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr KALBACHER Elsa

Tous les auteurs :
Chopard R, Badoz M, Eveno C, Ecarnot F, Falvo N, Kalbacher E, Capellier G, Guillon B, Schiele F, Meneveau N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33091699

Résumé

The safety and efficacy of direct oral anticoagulants (DOACs) in intermediate-high risk pulmonary embolism (PE) are unknown. The aims of the present study were to describe outcomes of patients receiving early apixaban or rivaroxaban prescription rather than the recommended delayed prescription strategy.

Mots clés

Cardiac biomarkers, Direct oral anticoagulant, Pulmonary embolism, Right ventricular dysfunction

Référence

Thromb Res. 2020 Oct 8;196:476-482